课题基金 / 基金详情

NEW RETROVIRAL RECEPTORS/HOST RESISTANCES

NEW RETROVIRAL RECEPTORS/HOST RESISTANCES
新的逆转录病毒受体/宿主耐药性
批准号:
6350407
负责人:
David Kabat
金额:
$24.68万
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-02-05 至 2005-01-31

项目摘要

项目成果

David Kabat的其他基金

相似基金

相关文献

中文摘要
翻译
直到最近,只有几个细胞逆转录病毒受体被分子克隆和功能鉴定。然而,使用一种强大的新策略,我们最近从人类T淋巴细胞cDNA文库中克隆了新的受体,包括小鼠白血病病毒(MLV)的异嗜性和多嗜性宿主群的共同受体(X-受体),导致猫普遍再生障碍性贫血的C型猫白血病病毒(FeLV-C)的受体(C-受体),以及RD 114猫内源性病毒的R-受体,该受体还介导了狒狒内源性病毒(BaEV)、禽网状内皮增生症病毒(REV)和灵长类D逆转录病毒的感染,这些病毒导致严重的免疫缺陷,据报道在人类艾滋病患者中是一种机会性感染。此外,我们还确定R-受体是广泛特异的中性氨基酸转运蛋白BO,X-受体参与Na+-磷酸共转运,C-受体是主要促进剂超家族成员。这些发现和方法为更好地了解这些和其他高致病性逆转录病毒提供了机会。我们建议:(I)分离小鼠的X-、R-和C-受体同源物,并利用人-鼠嵌合体和定点突变来确定这些受体上的活性部位和小鼠抵抗感染的机制。(Ii)相反,使用密切相关的异嗜性和多嗜性MLV包膜糖蛋白的嵌合体和定点突变体来鉴定控制这些病毒对不同品系小鼠的不同传染性的氨基酸(S)。因此,在病毒和X受体的水平上确定这种异质性的基础。(3)克隆对包括甲型肝炎病毒在内的其他逆转录病毒至关重要的细胞表面受体。(4)深入分析X、R、C受体的正常细胞功能。研究感染对这些功能的影响以及这些功能紊乱的致病后果。利用这些功能信息来优化基因治疗的转导效率。这些研究建立在一项技术突破的基础上,并将大大扩大我们对人类和动物逆转录病毒疾病以及宿主耐药机制的了解。
英文摘要
Until recently, only several cellular receptors for retroviruses had been molecularly cloned and functionally identified. However, using a powerful new strategy we recently cloned novel receptors from a human T lymphocyte cDNA library, including a common receptor (X-receptor) for xenotropic and polytropic host-range groups of murine leukemia viruses (MLVs), a receptor (C-receptor) for feline leukemia virus type C (FeLV-C), which causes prevalent aplastic amenias in cats, and the R-receptor for RD 114 feline endogenous virus that also mediates infections by baboon endogenous virus (BaEV), avian reticuloendotheliosis virus (REV) and the primate type D retroviruses that cause severe immunodeficiencies and have been reported as an opportunistic infection in a human patient with AIDS. In addition, we determined that the R-receptor is the broad specificity neutral amino acid transporter BO, that the X-receptor is involved in Na+-phosphate cotransport, and that the C-receptor is a member of the large MFS (major facilitator superfamily) of transporters. These discoveries and methods provide opportunities for improved understanding of these and other highly pathogenic retroviruses. We propose: (i) Isolate X-, R-, and C- receptor homologues from mice and use human-mouse chimeras and site-directed mutants to identify active sites in these receptors and the mechanisms for murine resistances to infections. (ii) Conversely, use chimeras and site-directed mutants of closely related xenotropic and polytropic MLV envelope glycoproteins to identify amino acid(s) that control the differential infectivity of these viruses for various strains of mice. Thereby, identify the basis for this xenotropism at the levels of both the virus and the X-receptor. (iii) Clone critically important cell surface receptors for other retroviruses, including FeLV-A. (iv) Thoroughly analyze the normal cellular functions of the X-, R-, and C- receptors. Study the effects of infection on these functions and the pathogenic consequences of these functional perturbations. Use this functional information to optimize transduction efficiencies for gene therapy. These investigations build on a technological breakthrough and will substantially expand our understanding of human and animal retroviral diseases and of host resistance mechanisms.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Drug development for Vif-APOBEC3G in HIV-1/AIDS
Drug development for Vif-APOBEC3G in HIV-1/AIDS
Drug development for Vif-APOBEC3G in HIV-1/AIDS
Role of Vif in HIV-1 Replication/AIDS
海外基金